Nemolizumab is an anti-IL-31 RA humanized monoclonal antibody that rapidly reduces itch in atopic dermatitis patients, with sustained efficacy, shows a suitable safety profile and decreases the itch–scratch cycle associated with AD patients, improving their quality of life. Here, IL31 is linked to atopic eczema.